INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of
A class action lawsuit has been filed against Medpace Holdings, Inc. (MEDP) alleging that the company issued false and misleading statements and/or failed to disclose material adverse facts regarding its projected book-to-bill ratio for Q4 2025. Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced significant losses are encouraged to contact Holzer & Holzer, LLC, by June 5, 2026, to discuss their legal rights. The lawsuit claims Medpace knowingly or recklessly disregarded the impact of cancellations on its book-to-bill ratio.
Medpace Investors Eligible to Lead Securities Fraud Lawsuit
The Schall Law Firm is reminding investors of a class action lawsuit against Medpace Holdings, Inc. for alleged violations of securities laws between April 22, 2025, and February 9, 2026. The lawsuit claims Medpace made false and misleading statements to inflate its share price, leading to investor losses. Investors who purchased securities during this period are encouraged to contact the firm before the June 5, 2026 deadline to participate.
Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Recommendation of "Hold" from Analysts
Medpace Holdings, Inc. (NASDAQ:MEDP) has received a consensus "Hold" rating from fifteen brokerages, with an average 12-month price target of $486.67. The company recently surpassed quarterly earnings and revenue estimates, reporting strong year-over-year revenue growth and setting optimistic FY2026 guidance. However, recent insider selling by President Jesse J. Geiger, who significantly reduced his holdings, adds a notable dynamic to the stock's profile.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged securities fraud. Investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to contact the firm before June 5, 2026, to participate. The lawsuit claims that Medpace made false and misleading statements and artificially inflated its share price, leading to investor damages.
Medpace (NASDAQ: MEDP) director converts 36 RSUs, now holds 32,789 shares
Medpace Holdings director Brian T. Carley converted 36 restricted stock units (RSUs) into 36 common shares on March 31, 2026, bringing his total direct holdings to 32,789 shares. This transaction, stemming from an RSU grant in November 2025, leaves him with 107 outstanding RSUs. The conversion occurred at a stated price of $0.00 per share, as detailed in the recent Form 4 SEC filing.
Medpace (MEDP) director exercises RSUs, lifts holdings to 922 shares
Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units (RSUs) on March 31, 2026, converting them into 33 shares of common stock. This transaction, part of a November 2025 RSU grant, increased his direct holdings to 922 common shares, with 97 RSUs remaining. The filing clarifies that this was an exercise of derivative securities, not an open-market purchase or sale.
PineStone Asset Management Inc. Sells 4,500 Shares of Medpace Holdings, Inc. $MEDP
PineStone Asset Management Inc. reduced its stake in Medpace Holdings, Inc. by 15.4% in Q4, selling 4,500 shares and now owning 24,700 shares valued at approximately $13.87 million. Concurrently, Medpace President Jesse J. Geiger sold over 31,000 shares for $14.44 million, lowering his stake to 20.3% ownership by insiders. Despite these sales, Medpace reported strong Q4 earnings, beating estimates with $4.67 EPS and $708.45 million in revenue, and analysts maintain a "Hold" consensus rating with a target price of $486.67.
[ARS] Medpace Holdings, Inc. SEC Filing
This article reports on Medpace Holdings, Inc.'s recent ARS SEC filing. The filing, categorized as an Annual Report to Security Holders, was accepted on April 1, 2026. The company, trading under NASDAQ: MEDP, is ranked #760 by market capitalization in the Diagnostics & Research industry.
Medpace Holdings, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into Medpace Holdings, Inc. for potential securities fraud, following a significant drop in Medpace's stock price on July 23, 2024. The decline occurred after the release of underperforming Q2 2024 financial results, which included unexpectedly high contract cancellations. The firm is encouraging affected Medpace investors to contact them to discuss their legal rights.
Medpace Holdings, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Medpace Holdings, Inc. following a significant drop in its stock price and disappointing Q2 2024 financial results. The firm is exploring potential securities fraud after Medpace's stock fell 18.3% due to high cancellation rates, impaired sponsor liquidity, and a terminated contract. Investors are encouraged to contact the firm for a complimentary case evaluation.
Medpace Holdings Inc (MEDP) Stock Price Quote Today & Current Price Chart
This article appears to be a stub or a placeholder, providing a title related to Medpace Holdings Inc (MEDP) stock price but containing no actual content beyond a generic tagline for an online trading app.
Polianta Ltd Invests $1.57 Million in Medpace Holdings, Inc. $MEDP
Polianta Ltd has purchased a new stake of 2,800 shares in Medpace Holdings, Inc. (NASDAQ:MEDP) valued at approximately $1.57 million during the fourth quarter. This acquisition is part of broader institutional investor activity, with hedge funds and institutional investors now owning 77.98% of Medpace's stock. The company recently beat EPS estimates, reported a 32% year-over-year revenue increase, and set strong FY2026 EPS guidance, while analysts maintain a "Hold" consensus rating.
Medpace Holdings Inc (MEDP) Shares Gap Down to $451.2 on Mar 30
Medpace Holdings Inc (MEDP) experienced a 3.30% drop in shares on March 30, reaching an intraday low of $449.11 before closing slightly higher at $451.20. This puts MEDP 28.26% below its 52-week high, with an average target price from analysts of $493.50, suggesting a 9.37% upside. GuruFocus also estimates a GF Value of $524.79, indicating a potential 16.31% upside from the current price.
Assenagon Asset Management S.A. Takes $4.08 Million Position in Medpace Holdings, Inc. $MEDP
Assenagon Asset Management S.A. has initiated a $4.08 million position in Medpace Holdings, Inc. (NASDAQ:MEDP) by acquiring 7,272 shares during the fourth quarter. This move comes as Medpace exceeded its quarterly earnings expectations, reporting an EPS of $4.67 against an estimated $4.18 and a 32% year-over-year revenue increase to $708.45 million, while also providing a strong FY2026 EPS guidance. Despite a recent sale of shares by company President Jesse J. Geiger, institutional investors hold a significant 77.98% ownership, and analysts maintain a consensus "Hold" rating with an average $486.67 price target.
Vanguard disaggregates holdings; reports 0% stake in Medpace (MEDP)
Vanguard Group has filed an amendment to its Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of Medpace Holdings Inc. common stock. This change is due to an internal realignment, where certain Vanguard subsidiaries and business divisions will now report their ownership separately, as per SEC Release No. 34-39538.
Riverbridge Partners LLC Has $153.31 Million Stake in Medpace Holdings, Inc. $MEDP
Riverbridge Partners LLC significantly reduced its stake in Medpace Holdings, Inc. ($MEDP) by 25.2%, now holding 272,969 shares valued at $153.31 million, making it their sixth-largest holding. Meanwhile, Medpace insiders like President Jesse J. Geiger also sold a substantial number of shares. The company recently exceeded Q4 earnings expectations with $4.67 EPS and $708.45M in revenue, and analysts currently have a consensus "Hold" rating on the stock with a $486.67 price target.
Norden Group LLC Has $7.32 Million Stock Position in Medpace Holdings, Inc. $MEDP
Norden Group LLC significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 956.6% in Q4, now holding 13,038 shares valued at $7.32 million. This increase makes Medpace its 24th largest holding, despite insider selling by President Jesse J. Geiger, who reduced his holdings by 67.9%. The company recently reported strong Q4 earnings, beating revenue and EPS estimates, and provided positive FY2026 EPS guidance.
Medpace Holdings Experiences Valuation Adjustment Amid Strong Performance Metrics
Medpace Holdings, a small-cap company, recently adjusted its valuation, currently boasting a P/E ratio of 29 and a remarkable ROE of 98.27%. Despite challenges with negative capital employed, the company delivered a strong 41.2% return over the past year, significantly outperforming the S&P 500. This highlights its competitive position, even with higher valuation metrics compared to some peers.
Ausbil Investment Management Ltd Grows Stake in Medpace Holdings, Inc. $MEDP
Ausbil Investment Management Ltd significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 111.4% in the fourth quarter of 2025, bringing its total holdings to 5,413 shares valued at $3.04 million. Despite substantial insider selling, particularly by President Jesse J. Geiger, analysts maintain a "Hold" consensus rating with an average price target of $486.67. Medpace reported strong Q4 earnings, beating estimates with $4.67 EPS and revenue of $708.45 million, and provided optimistic FY2026 EPS guidance.
Why Medpace (MEDP) Outpaced the Stock Market Today
Medpace (MEDP) shares outperformed the stock market, closing up 1.32% against the S&P 500's 0.54% gain. The company is set to report earnings on April 22, 2026, with anticipated increases in EPS and revenue, reflecting positive analyst sentiment and a current Zacks Rank of #3 (Hold). Investors are also evaluating its valuation metrics, including a Forward P/E of 27.04 and a PEG ratio of 2.21, both indicating a premium compared to industry averages.
Congress Asset Management Co. Has $33.91 Million Stake in Medpace Holdings, Inc. $MEDP
Congress Asset Management Co. reduced its stake in Medpace Holdings, Inc. by 6.7% in Q4, now holding 60,378 shares valued at approximately $33.91 million. Despite this, Medpace reported a strong Q4 beat, with EPS of $4.67 surpassing estimates and revenue increasing by 32%. Analysts currently rate Medpace as a "Hold" with an average target price of $486.67, even as insider Jesse J. Geiger recently sold a significant portion of his shares.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will release its first-quarter 2026 financial results after market close on April 22, 2026. The company will host a conference call on April 23, 2026, at 9:00 a.m. ET to discuss these results, with registration required for participation. A webcast and supplemental presentation will also be available on Medpace's investor relations website.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. announced it will report its first quarter 2026 financial results after market close on Wednesday, April 22, 2026. The company will host a conference call on Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. Interested parties are advised to register in advance for the conference call or access the webcast via Medpace's investor relations website, where a supplemental slide presentation will also be available.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will release its first quarter 2026 financial results after market close on April 22, 2026. A conference call to discuss these results will be held the following morning, April 23, 2026, at 9:00 a.m. ET. Interested parties must pre-register for the call or access a webcast via the Investors section of Medpace's website.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. announced it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The company will host a conference call on Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results, with registration and webcast details provided for interested parties. Medpace, a global clinical contract research organization, specializes in accelerating the development of medical therapeutics.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will release its first quarter 2026 financial results after market close on Wednesday, April 22, 2026. The company will then host a conference call on Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. Interested parties can register online for the conference call or access a webcast and supplemental presentation via Medpace's investor relations website.
Medpace Holdings Inc stock faces pressure amid clinical trial sector volatility
Medpace Holdings Inc (ISIN: US5840631062) shares experienced a significant drop, falling 7.09% to USD 442.83, amid broader volatility within the contract research organization (CRO) sector. This decline is attributed to increased competition and a potential slowdown in biotech funding, though the company's strong fundamentals, including 22.27% annual net sales growth and a 98.27% return on equity, suggest long-term potential. DACH investors are advised to monitor Medpace due to its robust growth in clinical trials and strategic positioning in complex oncology and rare disease studies, which are crucial for global drug development.
Strategic Sale: Jesse J Geiger Decides To Exercise Options Worth $10.24M At Medpace Holdings
Jesse J Geiger, President at Medpace Holdings (NASDAQ: MEDP), exercised stock options worth $10.24 million for 31,707 shares on March 19, as disclosed in an SEC filing. The company shows strong revenue growth of 32.03% and a healthy debt-to-equity ratio, indicating sound financial standing. Insider transactions, while not always definitive, can provide valuable insights into a company's prospects.
Medpace Holdings, Inc. Experiences Revision in Stock Evaluation Amid Competitive Landscape
Medpace Holdings, Inc. has adjusted its valuation metrics, with a P/E ratio of 29 and a price-to-book value of 28.11. The company has outperformed the S&P 500 over the past year but has seen a decline year-to-date, and its valuation is higher than some peers, indicating a competitive market. These metrics highlight the need for ongoing evaluation of Medpace's market position and financial health within the competitive landscape.
Medpace Holdings president sells $14.44M in stock By Investing.com
Jesse J. Geiger, President of Medpace Holdings Inc. (NASDAQ:MEDP), sold 31,707 shares of company stock for approximately $14.44 million after exercising options. The stock is currently trading at $460.92, up 40.75% over the past year, though an InvestingPro analysis suggests it might be slightly overvalued. The company has recently received several analyst upgrades and new coverage from firms like Barclays, RBC Capital, TD Cowen, Jefferies, and Baird, reflecting evolving sentiment and potential in the market.
Argent Capital Management LLC Sells 2,787 Shares of Medpace Holdings, Inc. $MEDP
Argent Capital Management LLC reduced its stake in Medpace Holdings, Inc. by 3.5% in the fourth quarter, selling 2,787 shares and now owning 76,340 shares valued at approximately $42.88 million. This comes as Medpace (NASDAQ:MEDP) reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue. Insider activity also saw President Jesse J. Geiger selling a significant portion of his holdings, while analyst ratings remain mixed with an average "Hold" recommendation.
Medpace Holdings president sells $14.44M in stock
Medpace Holdings Inc. President Jesse J. Geiger sold 31,707 shares of company stock for approximately $14.44 million after exercising options to acquire the same number of shares. This transaction follows several analyst upgrades and new coverage for Medpace, with firms like Barclays, RBC Capital, and Jefferies recognizing the company's improved valuation and potential in the biopharma market. The stock is currently trading at $460.92, up 40.75% over the last year.
Medpace (NASDAQ: MEDP) president exercises options, sells 31,707 shares
Medpace Holdings, Inc. (NASDAQ: MEDP) President Jesse J. Geiger exercised stock options for 31,707 shares at $138.87 per share and subsequently sold all 31,707 shares in an open-market transaction for a weighted average price of $455.30 per share. Following these transactions, Geiger directly holds 15,000 shares of Medpace common stock. The options had fully vested on February 15, 2026, and the sale involved multiple trades within a price range of $451.36 to $460.288 per share.
Medpace EVP exercises options for 12,000 shares | MEDP SEC Filing - Form 4
Medpace Holdings, Inc.'s Executive Vice President of Operations, Susan E. Burwig, exercised employee stock options for 12,000 shares of common stock at an exercise price of $166.73 per share on March 18, 2026. This transaction occurred after the options fully vested on October 27, 2025. Following the exercise, Burwig directly owns 70,484 shares of common stock and 11,028 derivative securities.
Medpace Holdings Inc Stock (ISIN: US5840631062) Faces Mixed Analyst Signals Amid Strong CRO Demand
Medpace Holdings Inc (MEDP) is experiencing robust growth driven by strong demand in the contract research organization sector, with its stock trading around $605 after an 82% year-to-date gain. Despite strong earnings and guidance, the company faces mixed analyst signals and insider selling, leading to a "Hold" consensus with varying price targets. European investors are showing interest in US CROs like Medpace due to outsourcing demand from stringent clinical regulations.
Dorsey Wright & Associates Makes New $5.08 Million Investment in Medpace Holdings, Inc. $MEDP
Dorsey Wright & Associates has made a significant new investment of $5.08 million in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 9,885 shares. This investment makes Medpace 1.1% of the firm's holdings and its 27th-largest position. The clinical research organization recently surpassed quarterly earnings expectations and provided strong FY2026 EPS guidance, although analyst sentiment remains mixed.
Medpace Holdings, Inc. (NASDAQ: MEDP) sets virtual annual meeting May 15, 2026
Medpace Holdings, Inc. (NASDAQ: MEDP) has announced its virtual 2026 Annual Meeting of Stockholders for May 15, 2026, where shareholders will vote on key proposals including the election of directors, auditor ratification, executive compensation, and significant amendments to the Certificate of Incorporation. The amendments aim to remove supermajority voting requirements and limitations on stockholders calling special meetings, transitioning to a more common majority voting standard and allowing stockholders owning 25% or more of voting stock to call special meetings. The company also reported strong 2025 financial results, exceeding its guidance with $2,530.2 million in revenue and $451.1 million in GAAP net income, influencing its compensation strategies which prioritize performance-based pay and competitive market positioning.
[144] Medpace Holdings, Inc. SEC Filing
Medpace Holdings, Inc. (MEDP) has submitted a Form 144 SEC filing, indicating a proposed sale of 31,707 shares of common stock with an aggregate market value of $14,513,879.25. The shares were acquired on March 17, 2026, through an option granted on February 15, 2022, from the issuer, with the sale expected on March 17, 2026, on NASDAQ through Fidelity Brokerage Services LLC. The filing shows a neutral impact and sentiment, detailing the specifics of the transaction and a standard representation from the filer confirming no undisclosed material adverse information.
Medpace Holdings, Inc. $MEDP Shares Sold by Mairs & Power Inc.
Mairs & Power Inc. reduced its stake in Medpace Holdings, Inc. by 8.7% in the third quarter, selling 6,603 shares and now holding 69,583 shares valued at approximately $35.78 million. Despite this sale, other institutional investors increased their positions, and Medpace reported stronger-than-expected quarterly earnings with a positive outlook for FY2026. Analyst sentiment is mixed, with a "Hold" consensus rating and an average target price of $486.67.
Brevan Howard Capital Management LP Reduces Stock Position in Medpace Holdings, Inc. $MEDP
Brevan Howard Capital Management LP reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 41.2% in the third quarter, selling 5,070 shares and now owning 7,241 shares valued at $3,723,000. Despite this, other hedge funds increased their positions, and 77.98% of the stock is held by institutional investors. Analysts have a "Hold" rating on Medpace with a consensus price target of $486.67, following its strong Q4 earnings, which beat estimates.
Medpace Holdings, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics
Medpace Holdings, Inc. has seen a valuation adjustment, with its stock currently priced at $450.41, building on a 41.67% return over the past year, significantly outperforming the S&P 500. The company, a small-cap player, exhibits strong financial metrics including a P/E ratio of 37 and impressive returns on capital employed (316.43%) and equity (242.70%). Despite its higher P/E compared to some peers, Medpace's consistent performance, including a three-year return of 158.40%, underscores its competitive market position.
Aquatic Capital Management LLC Purchases 17,146 Shares of Medpace Holdings, Inc. $MEDP
Aquatic Capital Management LLC significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 244.5% in the third quarter, purchasing an additional 17,146 shares and bringing its total to 24,158 shares valued at approximately $12.42 million. Other institutional investors also adjusted their positions in Medpace, which reported strong Q3 earnings, surpassing analyst expectations with $4.67 EPS and $708.45 million in revenue. The company maintains a "Hold" consensus rating from analysts, with an average price target of $486.67.
Is Medpace Holdings (MEDP) Still Appealing After Recent Volatility And Zelluna Partnership Expectations
Medpace Holdings (MEDP) has experienced mixed stock performance recently but is considered undervalued by Simply Wall St's DCF analysis, estimating its intrinsic value at $575.79 per share against a $450 current price. However, its P/E ratio suggests it might be overvalued compared to a proprietary "Fair Ratio." The article presents bullish and bearish narratives for MEDP, providing a valuation range between $352.16 and $582.00, influencing investors' perspectives on its attractiveness.
Is Medpace Holdings (MEDP) Still Appealing After Recent Volatility And Zelluna Partnership Expectations
Medpace Holdings (MEDP) has experienced recent stock volatility but shows a strong long-term return. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 21.8% at around $575.79 per share, while a Price-to-Earnings (P/E) ratio comparison indicates it might be overvalued at 28.34x compared to its proprietary "Fair Ratio" of 23.02x. The article presents bullish and bearish narratives, with fair value estimates ranging from $352.16 to $582.00 per share, influenced by factors like revenue growth, margins, and market sentiment, especially considering its role in clinical research and its Zelluna partnership.
Medpace Holdings, Inc. $MEDP Shares Purchased by Algert Global LLC
Algert Global LLC increased its stake in Medpace Holdings, Inc. ($MEDP) by 6.2% in Q3, now holding 41,809 shares valued at approximately $21.5 million. Medpace reported strong quarterly earnings, beating expectations with $4.67 EPS and $708.45 million in revenue, and provided optimistic FY2026 guidance. Analysts have a mixed view on the stock, with a consensus "Hold" rating and an average target price of $486.67.
Spyglass Capital Management LLC Trims Stock Position in Medpace Holdings, Inc. $MEDP
Spyglass Capital Management LLC reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 32.8% in Q3, selling 73,589 shares and holding 150,882 shares valued at $77.58 million. Despite this, Medpace reported strong Q4 results, beating EPS and revenue estimates, and provided positive FY2026 EPS guidance. While institutional ownership remains high at 77.98%, analysts maintain a "Hold" rating for the stock with a consensus target price of $486.67.
Does Barclays’ AI Reassessment Reframe Medpace (MEDP) as a Higher-Quality, More Durable Growth Story?
Barclays recently upgraded Medpace Holdings, suggesting that concerns about AI disrupting life sciences are overblown, reinforcing Medpace's solid fundamentals and institutional backing. While the upgrade supports Medpace's long-term growth narrative by reframing AI risks, the CAN SLIM analysis indicates shares are in a correction phase, meaning timing for entry is not optimal. Medpace's future growth hinges on converting its clinical backlog, especially in complex therapeutic areas, though client concentration remains a potential risk.
Medpace Holdings Hits Day Low of $442.83 Amid Price Pressure
Medpace Holdings, Inc. experienced a 7.09% decline, reaching an intraday low of $442.83, significantly underperforming the S&P 500. Despite this short-term drop, the company demonstrates strong long-term growth with a 22.27% annual increase in net sales and a 98.27% return on equity. Medpace maintains a solid market position with high institutional ownership and strong fundamentals.
Do options traders know something about Medpace stock we don't?
This article from MSN is currently empty and does not contain any content about Medpace stock or options trading. Therefore, no information can be extracted or summarized.
Does Barclays’ AI Reassessment Reframe Medpace (MEDP) as a Higher-Quality, More Durable Growth Story?
Barclays has upgraded Medpace Holdings (MEDP), suggesting that fears of AI disruption in life sciences are overblown and highlighting the company's strong fundamentals. While Medpace shows robust earnings and sales trends, its stock is currently in a correction phase according to CAN SLIM analysis. The upgrade reframes AI risk, but immediate catalysts remain clinical backlog conversion and the ongoing risk of sector-wide funding and trial cancellations.
